Javascript must be enabled to continue!
Cyr61 Expression is associated with prognosis in patients with colorectal cancer
View through CrossRef
Abstract
Background
Cysteine-rich 61 (Cyr61), a member of the CCN protein family, possesses diverse functionality in cellular processes such as adhesion, migration, proliferation, and survival. Cyr61 can also function as an oncogene or a tumour suppressor, depending on the origin of the cancer. Only a few studies have reported Cyr61 expression in colorectal cancer. In this study, we assessed the Cyr61 expression in 251 colorectal cancers with clinical follow up.
Methods
We examined Cyr61 expression in 6 colorectal cancer cell lines (HT29, Colo205, Lovo, HCT116, SW480, SW620) and 20 sets of paired normal and colorectal cancer tissues by western blot. To validate the association of Cyr61 expression with clinicopathological parameters, we assessed Cyr61 expression using tissue microarray analysis of primary colorectal cancer by immunohistochemical analysis.
Results
We verified that all of the cancer cell lines expressed Cyr61; 2 cell lines (HT29 and Colo205) demonstrated Cyr61 expression to a slight extent, while 4 cell lines (Lovo, HCT116, SW480, SW620) demonstrated greater Cyr61 expression than HT29 and Colo205 cell lines. Among the 20 cases of paired normal and tumour tissues, greater Cyr61 expression was observed in 16 (80%) tumour tissues than in normal tissues. Furthermore, 157 out of 251 cases (62.5%) of colorectal cancer examined in this study displayed strong Cyr61 expression. Cyr61 expression was found to be associated with pN (p = 0.018). Moreover, Cyr61 expression was associated with statistically significant cancer-specific mortality (p = 0.029). The duration of survival was significantly lesser in patients with Cyr61 high expression than in patients with Cyr61 low expression (p = 0.001). These results suggest that Cyr61 expression plays several important roles in carcinogenesis and may also be a good prognostic marker for colorectal cancer.
Conclusions
Our data confirmed that Cyr61 was expressed in colorectal cancers and the expression was correlated with worse prognosis of colorectal cancers.
Springer Science and Business Media LLC
Title: Cyr61 Expression is associated with prognosis in patients with colorectal cancer
Description:
Abstract
Background
Cysteine-rich 61 (Cyr61), a member of the CCN protein family, possesses diverse functionality in cellular processes such as adhesion, migration, proliferation, and survival.
Cyr61 can also function as an oncogene or a tumour suppressor, depending on the origin of the cancer.
Only a few studies have reported Cyr61 expression in colorectal cancer.
In this study, we assessed the Cyr61 expression in 251 colorectal cancers with clinical follow up.
Methods
We examined Cyr61 expression in 6 colorectal cancer cell lines (HT29, Colo205, Lovo, HCT116, SW480, SW620) and 20 sets of paired normal and colorectal cancer tissues by western blot.
To validate the association of Cyr61 expression with clinicopathological parameters, we assessed Cyr61 expression using tissue microarray analysis of primary colorectal cancer by immunohistochemical analysis.
Results
We verified that all of the cancer cell lines expressed Cyr61; 2 cell lines (HT29 and Colo205) demonstrated Cyr61 expression to a slight extent, while 4 cell lines (Lovo, HCT116, SW480, SW620) demonstrated greater Cyr61 expression than HT29 and Colo205 cell lines.
Among the 20 cases of paired normal and tumour tissues, greater Cyr61 expression was observed in 16 (80%) tumour tissues than in normal tissues.
Furthermore, 157 out of 251 cases (62.
5%) of colorectal cancer examined in this study displayed strong Cyr61 expression.
Cyr61 expression was found to be associated with pN (p = 0.
018).
Moreover, Cyr61 expression was associated with statistically significant cancer-specific mortality (p = 0.
029).
The duration of survival was significantly lesser in patients with Cyr61 high expression than in patients with Cyr61 low expression (p = 0.
001).
These results suggest that Cyr61 expression plays several important roles in carcinogenesis and may also be a good prognostic marker for colorectal cancer.
Conclusions
Our data confirmed that Cyr61 was expressed in colorectal cancers and the expression was correlated with worse prognosis of colorectal cancers.
Related Results
Abstract 1846: Cyr61 a therapeutic target for breast carcinomas
Abstract 1846: Cyr61 a therapeutic target for breast carcinomas
Abstract
Background: Cyr61, also known as CCN1, is a survival and pro-angiogenic factor overexpressed in invasive breast tumors that promotes tumorigenicity. We inve...
Abstract 1505: The effect of Cyr61 on oncolytic HSV-1 therapy for glioblastoma multiforme
Abstract 1505: The effect of Cyr61 on oncolytic HSV-1 therapy for glioblastoma multiforme
Abstract
Gliomas are the most prevalent primary brain tumor and categorized by WHO into four grades. Glioblastoma multiforme (GBM), the grade IV gliomas, have the wo...
Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes
Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes
Abstract
Background: The prevalence of peripheral artery disease (PAD) is obviously increased in patients with diabetes. Existing evidence shows that cysteine-rich angiogen...
Association of serum Cyr61 levels with peripheral arterial disease in patients with type 2 diabetes
Association of serum Cyr61 levels with peripheral arterial disease in patients with type 2 diabetes
Abstract
Background: The prevalence of peripheral artery disease (PAD) is obviously increased in diabetic patients. Existing evidences show that cysteine-rich angiogenic in...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis
MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis
Objective: In various cancers, migration and invasion inhibitory protein (MIIP) is expressed at low level and is involved in cancer pathogenesis. Herein, we sought to explore the f...
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance
Abstract
OBJECTIVE:
Colorectal cancer is a cancer with high prevalence and mortality rates worldwide, treated with surger...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

